Treatment of Prostate Cancer in the Rat with the Synthetic Retinoid Fenretinide

Kenneth J. Pienta, Nguyet M. Nguyen, Jeffrey E. Lehr, Meyer L. Prentis

Research output: Contribution to journalArticle

162 Scopus citations

Abstract

N-4-Hydroxyphenylretinamide (fenretinide or 4HPR), a derivative of retinoic acid, has been demonstrated to decrease the development of prostate cancer in a rat carcinogenesis model. This study was undertaken to determine if 4HPR is an effective agent for the treatment of established prostate cancer. In vitro, 4HPR was cytotoxic to rat and human prostate cancer cells as well as endothelial cells. Utilizing three different angiogen-esis inhibition assays, it was demonstrated that 4HPR inhibited angiogen-esis as well as endothelial cell motility and tubule formation. In vivo, 4HPR inhibited prostate cancer growth in a significant manner. These findings suggest that 4HPR may be a potent inhibitor of early prostate cancer growth.

Original languageEnglish
Pages (from-to)224-226
Number of pages3
JournalCancer research
Volume53
Issue number2
StatePublished - Jan 1993
Externally publishedYes

Fingerprint Dive into the research topics of 'Treatment of Prostate Cancer in the Rat with the Synthetic Retinoid Fenretinide'. Together they form a unique fingerprint.

  • Cite this

    Pienta, K. J., Nguyen, N. M., Lehr, J. E., & Prentis, M. L. (1993). Treatment of Prostate Cancer in the Rat with the Synthetic Retinoid Fenretinide. Cancer research, 53(2), 224-226.